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nificantly reduces UAE in hypertensive type 2 diabetic patientsLong-term comparison of losartan and enalapril on kidney func-
with early nephropathy. The reduction in UAE with each treat-tion in hypertensive type 2 diabetics with early nephropathy.
ment is similarly related to decrements in ABP. In addition,Background. The objectives of this study were to compare
the effects of the angiotensin II receptor blocker, losartan, to the rate of decline in GFR is similar in both treatment groups.
those of the angiotensin-converting enzyme inhibitor, enala-
pril, on albuminuria and renal function in relationship to clinic
and ambulatory blood pressure (ABP) in hypertensive type 2
Several rigorous longitudinal clinical studies havediabetic subjects with early nephropathy. The tolerability of
these agents and their effect on the metabolic profile were also demonstrated that increased urinary albumin excretion
evaluated. (UAE) predicts clinical proteinuria and increased mor-
Methods. The study was a one-year prospective, double-
tality. In addition, increased UAE also predicts increasedblind trial with losartan and enalapril administered alone or
morbidity, especially hypertension and cardiovascularin combination with hydrochlorothiazide and other antihyper-
tensive agents. ABP and renal and biochemical parameters disease, in non–insulin-dependent diabetes mellitus
were measured at baseline and after 12, 28, and 52 weeks of (NIDDM) or type 2 diabetic patients [1–4].
active treatment. Ninety-two hypertensive type 2 diabetics with Various studies have shown that treatment with angio-early nephropathy completed the study.
tensin-converting enzyme (ACE) inhibitors lowers bloodResults. Both losartan and enalapril administered alone or
in combination with other agents induced significant reductions pressure (BP) and reduces both albuminuria and the
in sitting clinic (P , 0.05) and ABP (P , 0.002) without a rate of decline in the glomerular filtration rate (GFR)
statistical difference between groups. Geometric means for in hypertensive type 2 diabetics with or without earlyurinary albumin excretion (UAE) decreased significantly (P ,
nephropathy [5–9]. Recently, a new class of drugs that0.001) in patients treated with losartan from 64.1 to 41.5 mg/
min and in those treated with enalapril from 73.9 to 33.5 mg/ selectively inhibits the renin-angiotensin-aldosterone
min after 52 weeks of therapy. A significant relationship (P , system (RAAS) by specifically targeting the angiotensin
0.05) between changes in systolic and diastolic ABP and the II type 1 (AT1) receptor has been developed for thedecrease in UAE at 52 weeks was seen in both groups. The
treatment of hypertension. Specific antagonists of thedecline in glomerular filtration rate (GFR) was stabilized at
the end of therapy and was identical in both treatment groups. AT1 receptor have been shown to be efficacious antihy-
Treatment with enalapril was associated with a significantly pertensive agents and are associated with a significantly
higher incidence of cough (P 5 0.006) and a rise in serum uric lower frequency of the unwanted adverse effects of ACEacid (P 5 0.002) compared with losartan.
inhibitors, such as cough [10, 11]. Moreover, these agentsConclusions. Our results indicate that a one-year course of
antihypertensive therapy with either losartan or enalapril sig- reduce proteinuria and maintain GFR as effectively as
ACE inhibitors in hypertensive patients with renal dis-
ease [12, 13]. A recent three-month study with losartanKey words: hypertension, NIDDM, early nephropathy, uric acid, anti-
hypertensive therapy. or enalapril performed in patients with essential hyper-
tension and normal renal function resulted in a similar
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UAE and renal function in hypertensive type 1 or type 2 medication titrated up to 10 mg o.d. if their SIDBP was
above 85 mm Hg, while those receiving losartan werediabetics.
Consequently, in the present study, we compared the maintained on 50 mg o.d. At week 8 of double-blind
treatment, uncontrolled subjects (SIDBP . 85 mm Hg)effects of 12 months of treatment with losartan, the first
available AT1 antagonist, to those of the ACE inhibitor of both groups had their medication doubled. At week
12, subjects with SIDBP . 85 mm Hg were given aenalapril on UAE and the relationship to clinic and am-
bulatory BP reduction in hypertensive type 2 diabetics combination of losartan or enalapril plus hydrochlorothi-
azide (HCTZ) 12.5 mg titrated to 25 mg to achieve awith persistent increased UAE. A secondary objective
was to monitor GFR during antihypertensive therapy. goal SIDBP of 85 mm Hg. Additional antihypertensive
agents other than ACE inhibitors, AT1 antagonists, andIn addition, we evaluated the tolerability of these agents
and their effects on the metabolic profile. calcium channel blockers were then prescribed to achieve
goal BP control. Early up-titration was permitted starting
at week 4 for patients having SIDBP .105 mm Hg. At
METHODS
week 20 of double-blind therapy, subjects with SIDBP .
This multicenter, double-blind study was conducted 100 mm Hg were discontinued from the study. No planned
at eight clinical centers in Canada. Institutional review modification was made in the subject’s usual insulin or
board approval was obtained from each center, and all antihyperglycemic agent regimen throughout the study.
patients gave their informed consent. All procedures In addition to the subject’s continuous autosurveillance
performed in this study were conducted in accordance of their glycemia, chemical indices of control such as
with institutional guidelines. glycated hemoglobin (HbA1C) and plasma glucose level
were determined at regular intervals. The subject’s diets
Patient selection
were unchanged, with no sodium or protein restriction.
Male and female outpatients with type 2 diabetes mel- The antihypertensive effects of the study medications
litus diagnosed at 30 years of age or later, mild to moder- were evaluated by the results of the clinic BP measure-
ate essential hypertension [sitting diastolic BP (SIDBP) ments and ABPs. Clinic BP was measured at each visit
90 to 115 mm Hg], and early nephropathy characterized between 7 and 10 a.m., 24 hours after medication inges-
by a UAE rate 20 to 350 mg/min without evidence of tion (range 22 to 26 h), with a standard mercury sphyg-
urinary tract infection were screened for enrollment. momanometer and an appropriately sized cuff, and with
Exclusion criteria included evidence or suspicion of Korotkoff phases I and V for the systolic and diastolic
renovascular disease, history of malignant hypertension, values, respectively. All readings were performed in trip-
systolic BP . 210 mm Hg, cerebrovascular accident in licate in both sitting and standing positions after a five-
the previous 12 months or current transient ischemic minute rest period. Values were then averaged. Twenty-
attacks, myocardial infarction within the previous 12 four–hour ambulatory BP was measured noninvasively
months, clinically significant arteriovenous (AV) con- at 20-minute intervals, between 7 a.m. and 10 p.m. (day-
duction disturbances and/or arrythmias, unstable angina, time) and at 30-minute intervals between 10 p.m. and
history of heart failure, serum creatinine $200 mmol/L, 7 a.m. (nighttime), using the Spacelabs model 90207
serum potassium $5.5 mmol/L or #3.5 mmol/L, treat- (Spacelabs M.C., Redmond, WA, USA) oscillometric
ment with oral corticosteroids, concomitant use of agents device. ABP monitoring occurred four times during the
that may affect BP except b-blockers and nitrates used study: at the end of the placebo run-in period and after
in the treatment of stable angina, drug or alcohol abuse, 12, 28 and 52 weeks of the double-blind period. Monitor-
pregnancy, breast feeding, and ineffective contraception. ing accuracy was validated against a conventional mer-
cury sphygmomanometer using a t-tube connector [15].
Study design The following quality-control criteria were established
After screening assessment, current antihypertensive as standards for acceptability for each ABP monitoring
medications, other than b-blockers and/or nitrates for report: (1) a minimum of 24 hours of data postdose,
patients with stable angina, were discontinued during a (2) a minimum of 50 total valid readings (80% of total
washout period of seven days (14 days for ACE inhibitor- readings), (3) a minimum of 22 total valid reading hours,
treated subjects). A two- to four-week single-blind pla- and (4) no two consecutive invalid hours. Twenty-four–
cebo run-in period was followed by a 16-week titration hour daytime and nighttime BP values were derived from
period and a 36-week maintenance period. At the end the arithmetic mean of all the values recorded during
of the run-in period, subjects with a clinic SIDBP of 90 the corresponding periods.
to 115 mm Hg and increased UAE were randomized to Laboratory evaluations, including hematology, chem-
double-blind treatment with either losartan 50 mg or istry, HbA1C, lipid profile, and urinalysis, were performed
enalapril 5 mg o.d. in a 1:1 ratio, within each center. during the baseline period and after 4, 12, 28, and 52
weeks of active treatment. Tolerability of study treat-Four weeks later, patients receiving enalapril had their
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Table 1. Patient characteristics at baselinement was assessed by monitoring of spontaneous reports
of adverse experiences at each visit. UAE was measured Losartan Enalapril
(N 5 52) (N 5 51)on three consecutive days, utilizing timed overnight (8
to 12 hour) urine collections [16] during the baseline Gender
Male 39 44period and after 12, 28, and 52 weeks of active treatment.
Female 13 7Analysis of albumin concentration was made by radioim- Mean age (SD) 59.2 (9.2) 57.8 (10.5)
munoassay (Pharmacia Albumin RIA; Pharmacia Diag- Race (N)
Caucasian 50 49nostic AB, Uppsala, Sweden). The mean of the three
Oriental 1 2samples was calculated. A urine culture was performed Black 1 0
if subjects had symptoms of urinary tract infection. These Mean sitting clinic BP mm Hg (SD)
Systolic 162.3 (16.2) 157.7 (15.9)subjects could be enrolled when their urine culture be-
Diastolic 97.2 (6.3)a 95.3 (4.8)came negative. GFR was estimated, at the same time
Weight kg (SD) 92.4 (17.2) 91.5 (19.8)
points as UAE, by the plasma disappearance of 51CR- Mean duration of diabetes years (SD) 9.2 (7.5)b 12.6 (8.4)
Mean age at diabetes diagnosisethylenediaminetetraacetic acid (EDTA). The values
years (SD) 49.7 (10.7)c 45 (10.6)were standardized for a body surface area of 1.73 m2 [17].
Mean UAE (geometric means)
lg/min 64.1 73.9Statistical analysis
aP 5 0.025; bP 5 0.031 vs. enalapril
Data from Lacourcie`re et al [7] and Chan et al [18] cP 5 0.039 vs. losartan
were used for the power calculation. The calculation was
carried out on the variable defined as LOG10 (UAE at
exit/UAE at baseline). Assuming 40 evaluable subjects
pleted the study, 46 subjects in each treatment group.in each group, a power of 80% and a 5 0.05 (two tailed)
There were 49 subjects in each group included in thewere calculated in order to detect a within-group change
intention-to-treat analysis for UAE at week 52. Six sub-from baseline in log UAE of 0.20 or greater. With the
jects were discontinued from the study in the losartansame conditions and level of power, the detectable differ-
group and five in the enalapril group. Two subjects, oneence between groups for the change from baseline in log
in each group, were withdrawn for uncontrolled hyper-UAE is 0.27 or greater.
tension, while one subject in the losartan group wasAll analyses were performed using version 6.12 of the
SAS statistical package. All statistical comparisons were discontinued as a result of urticaria and one in the enala-
based on two-sided tests. Statistical significance of treat- pril group as a result of cough. Deviations from protocol
ment comparisons was declared if the probability value account for the discontinuation of four subjects in the
was less than or equal to 0.05 for each time point. Treat- losartan group and two in the enalapril group. Another
ment differences were evaluated using analysis of vari- subject in the enalapril group voluntarily withdrew his
ance (ANOVA) on the change from baseline considering consent. There were no deaths nor any cardiovascular
an intention-to-treat approach. A two-way ANOVA events during the course of this study. Baseline gender
model with treatment effect, center effect, and treat- distribution, race, age, and weight were similar in the
ment-by-center interaction was used. The latter interac- two groups (Table 1). However, SIDBP at baseline was
tion term was removed if there was no evidence of sig- higher in the losartan group (P 5 0.025), and the mean
nificant interaction (P . 0.10). The qualitative and duration of diabetes was longer (P 5 0.039) in the losar-
quantitative nature of the interaction involving treat- tan group.
ment effects on UAE was tested by the method of Gail By the end of 52 weeks of active treatment, 20 out of
and Simon. Calculations of UAE and GFR were per- 52 subjects in the losartan group received monotherapy
formed on log-transformed values and were presented (38.5%), and 31 out of 52 required combination therapy
as geometric means. Skewness in the distribution of the
with HCTZ (59.6%), including 12 patients on triple ther-data was corrected by log transformation. The normality
apy (23%). One patient randomized to losartan neverand homogeneity of the variances were verified by the
received any treatment. In the enalapril-treated group,Shapiro–Wilk test and the Levene test, respectively. Cor-
25 out of 51 subjects received monotherapy (49%), andrelations between changes in BP and UAE were evalu-
26 out of 51 received combination therapy with HCTZated by Pearson’s analysis. The safety of treatments was
(51%), including five patients on triple therapy (5.8%).assessed by means of Fisher’s exact test.
The mean dose (SD) of losartan was 86.3 (22.5) mg
versus 16.0 (6.2) mg for enalapril. Mean doses of HCTZ
RESULTS were 23.0 (4.7) mg for the losartan group and 21.6 (5.7)
Study population mg for the enalapril group. Triple therapy consisted of
losartan or enalapril plus HCTZ and b- or a1-adrenore-Of the 103 hypertensive type 2 diabetics who entered
the double-blind treatment period, 92 (89.3%) com- ceptor blockers. There were no significant differences in
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Table 2. Ambulatory blood pressure responses (mean changes mm Hg)a to losartan and enalapril
Losartan (N 5 38) Enalapril (N 5 40)
Baseline 12 week 28 week 52 week Baseline 12 week 28 week 52 week
Systolic
24 hour 158.4 149.4 (29.0) 142.8 (215.7) 144.0 (214.4) 153.7 143.4 (210.3) 138.2 (215.5) 138.3 (215.4)
Day 162.8 154.0 (28.8) 146.1 (216.8) 147.2 (215.6) 159.9 147.8 (212.1) 142.6 (217.3) 142.7 (217.2)
Night 150.0b 143.9 (26.1) 135.7 (214.3) 136.4 (213.6) 144.0 136.2 (27.9) 130.9 (213.1) 130.0 (214.0)
Diastolic
24 hour 89.7 84.8 (25.0) 80.7 (29.0) 81.2 (28.6) 88.4 82.4 (26.0) 79.7 (28.7) 78.8 (29.6)
Day 93.1 87.8 (25.3) 83.3 (29.8) 83.7 (29.4) 92.7 86.2 (26.6) 83.4 (29.4) 82.6 (210.1)
Night 83.9 79.0 (25.0) 75.1 (28.8) 74.9 (29.0) 80.8 75.8 (25.1) 73.7 (27.1) 71.9 (28.9)
Day from 7 am to 10 pm; night, from 10 pm to 7 am.
aSignificantly different (P # 0.002) from baseline for all values
bP , 0.05 vs. enalapril
the use of combination therapy (P 5 0.324) or in the
use of other antihypertensive agents (P 5 0.11) for the
two groups of patients. ABP was performed on willing
subjects only at five of the eight sites. Of the 89 subjects
who entered the study at the five centers, 78 provided
acceptable and evaluable ABP measurements, 38 sub-
jects in the losartan group and 40 in the enalapril group.
The three sites that did not participate in the ABP moni-
toring preferred to be exempt from carrying out this
procedure on their patients, as they were not completely
familiar with the technique. There was no significant
change in body weight as well as in dietary protein con-
Fig. 1. Urine albumin excretion in the losartan (j) and enalapril (s)sumption in the treatment groups during the trial.
groups. Both treatments induced significant reductions from baseline
in albuminuria at either 12, 28, or 52 weeks of therapy. Error barsEffects on blood pressure represent 95% confidence intervals. *P 5 0.027; **P , 0.001 vs. baseline.
After 52 weeks of active treatment, both losartan and
enalapril administered alone or in combination with
other agents significantly decreased (P , 0.005) clinic
had UAE 200 to 300 mg/min. Three patients with mi-sitting systolic BP (SISBP) and SIDBP without a clear-
croalbuminuria upon enrollment raised their UAE .cut difference between the two treatment groups. Indeed,
200 mg/min during the placebo run-in period. There waslosartan decreased sitting BP from 163.3 (16.2)/97.2 (6.3)
no statistically significant difference between groups inmm Hg to 148.3 (17.1)/86.8 (9.6) mm Hg. On the other
UAE at baseline. The mean decrease in UAE was sig-hand, enalapril decreased sitting BP from 157.7 (15.9)/
nificant by week 12 (P # 0.027) in both treatment groups95.3 (4.8) mm Hg to 145.5 (18.2)/84.4 (8.4) mm Hg. Mean
and remained significantly lower (P , 0.001) than base-changes in standing BP were similar to changes observed
line values throughout the study period. Albuminuriain the sitting position. The percentage of subjects who
(geometric means) decreased from 64.1 mg/min at base-achieved goal SIDBP of # 85 mm Hg at the end of the
line to 55.1, 36.8, and 41.5 mg/min after 12, 28, and 52study was 49% in the losartan group and 51% in the
weeks, respectively, in the losartan group, and from 73.9enalapril group.
mg/min to 50.7, 39.4, and 33.5 mg/min for the same timeBaseline ABP levels were higher in the losartan group
intervals, in the enalapril group (Fig. 1). There was noduring each period, although statistical difference was
significant difference between groups with respect to thedemonstrated only for nighttime systolic BP (Table 2).
change from baseline in LOG UAE after 12 and 28Both losartan and enalapril administered alone or in com-
weeks of treatment. At week 52, analyses showed a sig-bination with other antihypertensive agents were effective
nificant quantitative treatment-by-center interactionin reducing BP during 24-hour daytime and nighttime
characterized by a variation in the magnitude of treat-periods, without statistical differences between groups.
ment differences from center to center. The difference
Effects on urinary albumin excretion between groups with respect to the change from baseline
in LOG UAE is not significant when the interaction isOf the 103 randomized subjects, 93 had baseline UAE
20 to 200 mg/min (microalbuminuria), and 10 subjects taken into account and significant (P 5 0.026) otherwise.
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Fig. 2. Relationship between the changes in
ambulatory blood pressure (ABP) and the
changes in Log urinary albumin excretion
(UAE) for losartan (N 5 38; e) and enalapril
(N 5 40; 3) groups at week 52 is illustrated
by the regression lines fitted to the data points
of the scatter plot. Losartan (LOS) slope 5
0.0395, Enalapril (ENA) slope 5 0.0495. P 5
0.69 between groups; r 5 0.34, P 5 0.039 for
LOS; r 5 0.42, P 5 0.007 for ENA (error bars
represent 95% confidence units on regression
means).
The observed numeric difference should therefore be
interpreted with caution.
Changes in LOG UAE correlated significantly (P ,
0.05) with changes in 24-hour systolic or diastolic ABP
and nighttime systolic ABP (mm Hg) at week 52, for
both treatment groups combined. Analyzing each group
separately, the correlation obtained with changes in 24-
hour systolic ABP was r 5 0.31, P 5 0.057 for losartan
and r 5 0.41, P 5 0.008 for enalapril. A significant corre-
lation (P , 0.05) was obtained with changes in 24-hour
diastolic ABP (Fig. 2) for each group (r 5 0.34 for losar-
tan and r 5 0.42 for enalapril). With changes in nighttime
systolic ABP, the correlation was r 5 0.33, P 5 0.045
Fig. 3. Glomerular filtration rate (GFR) in the losartan (j) and enala-for losartan and r 5 0.31, P 5 0.051 for enalapril. There
pril (s) groups. Both treatments induced a significant reduction fromwere no statistical differences between the two treatment baseline in GFR that plateaued after 52 weeks of therapy. Error bars
groups for any of the correlation coefficients obtained. represent 95% confidence intervals. *P 5 0.006 for losartan; **P ,
0.001 for both losartan and enalapril versus baseline.Accordingly, there was no statistical difference in the
linear relationship (regression slope) of the changes from
baseline in Log UAE with respect to the changes from
baseline in ambulatory BP at week 52 between the two treatment. The GFR fall during the first 12 weeks was
groups. In contrast, the reduction in UAE was less well positively related to the degree of 24-hour mean systolic
correlated with the reduction in clinic BP. A significant (r 5 0.24, P , 0.05) and diastolic (r 5 0.23, P , 0.05)
but weaker correlation (r 5 0.23, P 5 0.022) was seen ABP decrements. However, the correlation was no
with the change in SIDBP for both groups combined. longer significant after 28 and 52 weeks of treatment.
Again, there was no statistical difference between treat-
Clinical and laboratory safetyments.
There were no significant differences between the lo-
Effects on renal function sartan and enalapril treatment groups in the frequency of
Baseline GFR (geometric mean) was nearly identical total clinical adverse experiences. However, treatment-
for the losartan (96.7 mL/min)- and enalapril (95.3 mL/ related cough occurred significantly more frequently in
min)-treated subjects (Fig. 3). A similar decline in GFR those subjects taking enalapril (14% vs. 0%; P 5 0.006).
was observed with each treatment group starting at week Two subjects (one with dyspnea and the other one with
12. The overall decline of approximately 9% between urticaria) in the losartan group and one subject with
baseline and week 52 was significant (P # 0.001) in both cough in the enalapril group discontinued the active
treatment because of adverse clinical experiences.groups. The rate of decline plateaued by the end of
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There were no significant changes in serum glucose. compared with the losartan group seen at week 52. How-
ever, taking into account individual changes in ABP, theThe median value for HbA1c at baseline tended to be
lower in the losartan group (0.077) compared with the linear relationship of the changes from baseline in Log
UAE with respect to the changes from baseline in ABPenalapril group (0.085). There were slight but statistically
significant (P # 0.005) increases in both groups at week was similar in both treatment groups.
Some center-to-center variation is to be expected in28. The change from baseline remained significant in the
losartan group, but not in the enalapril group, at the end multicenter studies. In the present study, there is a treat-
ment-by-center interaction whereby the treatment dif-of the study. HbA1c median changes were 10.006 for
losartan and 10.0025 for enalapril at week 52. Subjects ferences across centers vary significantly in magnitude.
Possible sources of interaction include factors such asin both groups remained within the range of fair diabetic
control throughout the study as assessed by this labora- the duration of diabetes at entry and age at the time of
diagnosis of the disease. As discussed earlier, anothertory parameter. There were statistically significant (P ,
0.05) median changes at week 52 in total cholesterol factor that can explain differences in the effect of the
two treatments on UAE is the change in ABP. The(2.1 and 4.2% decrease within the losartan and enalapril
group, respectively), triglycerides (11.3% decrease in the extent to which decreases in ABP and UAE are corre-
lated suggests that the antiproteinuric effects of AT1enalapril group), and low-density lipoproteins (6.5% de-
crease in the losartan group). antagonists and ACE inhibitors may also be mediated by
other mechanisms such as distinct renal effects involvingOf particular interest is the magnitude of changes in
serum concentration of uric acid. Median changes of microcirculation changes and tissue remodeling. The con-
cept that the renal effects of AT1 antagonists and ACE222.0 mmol/L in the losartan group and of 112.0 mmol/L
in the enalapril group (P 5 0.001 enalapril vs. losartan) inhibitors are mediated by interference on the RAAS
rather than the kinin-kallikrein system is supported bywere observed after 12 weeks of monotherapy. After 52
weeks of active monotherapy or combination therapy, the results of other studies showing similar systemic and
hemodynamic effects of these agents [12, 27].median changes of 12.0 mmol/L in the losartan group
Another important aim of the present study was toand of 130.0 mmol/L in the enalapril group (P 5 0.002
compare the effects of AT1 antagonists and of ACEenalapril vs. losartan) were observed.
inhibitors on GFR in hypertensive type 2 diabetics. Our
data provide the first long-term evidence, to our knowl-
DISCUSSION edge, that AT1 antagonists have similar effects to ACE
The main purpose of this long-term double-blind study inhibitors on the rate of decline in GFR. The decrease
was to compare the effects of the AT1 antagonist losartan in GFR during the first three to seven months after
to those of the ACE inhibitor enalapril on kidney func- the start of antihypertensive therapy is consistent with
tion in hypertensive type 2 diabetics with early nephropa- previous studies using ACE inhibitors [6, 28] and is most
thy. Our results indicate that UAE was significantly re- likely caused by an hemodynamic-induced redistribution
duced with both losartan and enalapril treatments. The of kidney blood flow, secondary to the abrupt lowering
observed anti-albuminuric effect of losartan in this study of systemic BP. Further studies are, however, required
is consistent with results from previous studies in which to examine whether longer term intensive control of BP
AT1 antagonists reduced proteinuria [12–14]. with AT1 antagonists can stabilize the decline in GFR
Ambulatory BP monitoring is a well-established method and delay the loss of renal function, as previously demon-
that allows the determination of circadian variations of strated with ACE inhibitor therapy [28, 29].
BP and the efficacy of antihypertensive treatment [19]. Despite the beneficial clinical effects related to inter-
Moreover, ABP monitoring has been found to be more ference on the RAAS, the high prevalence of cough
closely related to target organ damage [20, 21] and to associated with ACE inhibitors has reduced their general
cardiovascular mortality than clinic BP [22, 23]. Further- acceptability. In the present study, cough was not in-
more, clinic BP has been found to be less closely related duced by losartan, while the incidence was 14% in the
to microalbuminuria than ABP in patients with essential enalapril treated patients. These findings are in agree-
hypertension [24] and in those with type 2 diabetes melli- ment with a previous study showing that the cough ob-
tus [25]. In the present study, there is a correlation be- served with ACE inhibitors does not occur with the AT1
tween the decreases in ABP and UAE. These results antagonists [11]. Thus, treatment with these new agents
are in agreement with those of Bauduceau et al, who may offer a valuable alternative for patients with ACE
have shown that ABP decrease is a valuable predictor inhibitor-related cough.
of UAE decrease in hypertensive type 2 diabetics [26]. Although raised serum uric acid concentration is com-
The significant correlation between ABP decrease and monly encountered in hypertensive patients, contradic-
the changes in UAE may explain, at least in part, the tory evidence exists as to whether serum uric acid is a
cardiovascular risk factor [30, 31]. As reported earlier,apparently greater UAE decline in the enalapril group
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hibitor enalapril in patients with essential hypertension. J Hyper-in the present study uric acid remained stable in the
tens 13:1343–1351, 1995
losartan treated patients in spite of the fact that a greater 11. Lacourcie`re Y, Brunner A, Irwin R, Karlberg BE, Ramsay LE,
number of subjects required concomitant administration Snavely DB, Dobbins TW, Faison EP, Nelson EB, the Losartan
Cough Study Group: Effects of the modulators of the renin-of HCTZ [32, 33]. The increased in uric acid excretion
angiotensin-aldosterone system on cough. J Hypertens 12:1387–
mediated by losartan may theoretically correct the rela- 1397, 1994
tively diminished uric acid excretion rate in hypertensive 12. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric
effects of ACE Inhibition mediated by interference in the renin-patients [34]. However, the beneficial influence of losar-
angiotensin system? Kidney Int 45:861–867, 1994tan on the frequency of gout attacks in hypertensive 13. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong
patients treated or not with diuretics versus ACE inhibi- PE: Effects of the angiotensin II antagonist losartan in hypertensive
patients with renal disease. J Hypertens 12:S37–S42, 1994tor or other antihypertensive treatments remains to be
14. Nielsen S, Dollerup J, Nielsen B, Jensen HAE, Mogensen CE:established in prospective studies. Losartan reduces albuminuria in patients with essential hyperten-
In conclusion, in hypertensive type 2 diabetics with sion: An enalapril controlled 3 months study. Nephrol Dial Trans-
plant 12(Suppl 2):19–23, 1997early nephropathy, treatment for 12 months with losar-
15. Graettinger WF, Lipson JL, Cheung DG, Weber MA: Validationtan or enalapril reduced UAE significantly and showed of portable noninvasive blood pressure monitoring devices: Com-
a similar response in UAE reduction with respect to parison with intraarterial and sphygmomanometer measurements.
Am Heart J 116:1155–1160, 1988the decrease in ABP. Long-term studies are required
16. Mogensen CE, Chachati H, Christensen CK: Microalbuminuria,to examine whether the antiproteinuric effects of AT1 an early marker of renal involvement in diabetes. Uremia Invest
antagonists confer significant renoprotection. 9:89–95, 1985
17. Bru¨chner-Mortensen J, Rodbro P: Selection of a routine method
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